Medtronic's recent regulatory approvals should bode well for non-GAAP EPS growth in the coming years. Read why I am ...

The US FDA has granted approval for the use of Medtronic’s disposable Simplera Sync sensor with the MiniMed 780G system.

Medtronic offers a compelling long-term investment opportunity with solid revenue and earnings growth, driven by innovation ...

Medtronic noted that the system's "treat to ... Last month, the company reported the two-year outcomes from the SMART trial of the Evolut transfemoral transcatheter aortic valve replacement ...

Notably, Medtronic holds the esteemed designation of a Dividend Aristocrat for investors who prioritize reliability. This ...

Medtronic (NYSE:MDT), a leading global healthcare technology company, stands out as a compelling option. It offers a distinctive combination of defensive traits and growth opportunities driven by ...

Medtronic recently announced the FDA approval for its Simplera Sync sensor, enhancing the MiniMed 780G system with significant technological advancements. Over the past week, Medtronic's share ...

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the ...